Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review

• Main Authors: Takamichi Yokoe, Ippei Fukada, Kokoro Kobayashi, Tomoko Shibayama, Yumi Miyagi, Atsushi Yoshida, Takuji Iwase, Shinji Ohno, Yoshinori Ito
• Format: Article
• Language: English
• Published: Karger Publishers 2017-07-01
• Series: Case Reports in Oncology
• Subjects: Cystoid macular edema; Macular edema; Optical coherence tomography; Paclitaxel; Bevacizumab; Breast cancer
• Online Access: http://www.karger.com/Article/FullText/477897

We present a case of a metastatic breast cancer patient with cystoid macular edema (CME) occurring during treatment with paclitaxel and bevacizumab. She had a history of neoadjuvant chemotherapy and partial mastectomy plus axillary lymph node dissection for stage IIB left-breast cancer. Twenty-four months later, she was diagnosed with multiple bone metastases and underwent chemotherapy with paclitaxel and bevacizumab. Thirty-three months after the initiation of the chemotherapy, she noticed bilateral blurred vision. The retinal thickening with macular edema was observed by optical coherence tomography, resulting in a diagnosis of CME. With cessation of paclitaxel and administrating ocular instillation of a nonsteroidal anti-inflammatory drug, her macular edema gradually reduced and disappeared in a month. While CME caused by chemotherapy is very rare, taxane may cause ocular adverse events such as CME. It is important to urge patients to consult an ophthalmologist promptly when they have visual complaints during taxane chemotherapy.